The FDA has granted Rare Pediatric Disease Designation to Marinus Pharmaceuticals’ (MRNS +3.1%) for its product candidate ganaxolone, an allosteric modulator of GABAA receptors, for CDKL5 deficiency disorder (CDD), a rare refractory form of pediatric epilepsy.

CDD is characterized by early‑onset, difficult‑to‑control seizures and severe neuro‑developmental impairment.

Rare Pediatric Disease Designation provides for the issuance of a priority review voucher following FDA approval. The voucher can be used for accelerated approval of future marketing application or it can be sold to a third party.





Source link

Comments to: Marinus Pharma’s Ganaxolone nabs Rare Pediatric Disease tag for rare pediatric epilepsy (NASDAQ:MRNS)

Your email address will not be published. Required fields are marked *

Attach images - Only PNG, JPG, JPEG and GIF are supported.

Login

Welcome to Typer

Brief and amiable onboarding is the first thing a new user sees in the theme.
Join Typer
Registration is closed.